Bavarian Nordic
154.95 DKK -0.1%HC Andersen Capital receives payment from Bavarian Nordic for a DigitalIR/Corporate Visibility agreement. See disclaimer.
24 investors are following this company
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Revenue
7.06B
EBIT %
21.28 %
P/E
8.07
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BAVA
Daily low / high price
154.1 / 155.8
DKK
Market cap
12.1B DKK
Turnover
30.08M DKK
Volume
194K
Latest videos
Financial calendar
General meeting
2024-04-16
Interim report
2024-05-08
Interim report
2024-08-22
Interim report
2024-11-15
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
ATP Group | 10.1 % | 10.1 % |
Invesco | 5.0 % | 5.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools